title: Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk.
abstract: Circulating insulin-like growth factors (IGFs) and their binding proteins have been associated with increased risk of breast, prostate, colon, and lung cancer. To examine the association of IGFs and endometrial cancer risk, we measured the plasma levels of IGF-1, IGF-2, and IGF binding protein 3 (IGFBP-3) by ELISA in 80 women with endometrial cancer and 80 age-matched control subjects with no history of cancer. Mean plasma levels of IGF-2 were significantly higher in women with cancer versus controls (670 ng/ml versus 380 ng/ml, P < 0.001). In contrast, significantly lower mean plasma levels of IGF-1 (155 mg/ml versus 185 ng/ml, P < 0.01) and IGFBP-3 (1703 ng/ml versus 2170 ng/ml, P < 0.001) were observed among cases compared to the control group. Women in the highest quartile of IGF-2 were found to have 9.67 (95% confidence interval 3.29-28.43) times the risk of endometrial cancer than women in the lowest quartiles. Women in the highest quartile of IGFBP-3 were associated with a significantly decreased risk for developing endometrial cancer (odds ratio = 0.23, 95% confidence interval 0.09-0.60). These data suggest that increased plasma levels of IGF-2 and decreased levels of IGFBP-3 are associated with an increased risk of endometrial cancer. Further validation of these results is needed to determine the potential usefulness of risk assessment.
authors.affiliation: The Department of Gynecological Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030,USA.
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Oh
authors.forename: Weiguo
authors.initials: W
authors.lastname: Wu
authors.forename: Guillermo
authors.initials: G
authors.lastname: Tortolero-Luna
authors.forename: Russell
authors.initials: R
authors.lastname: Broaddus
authors.forename: David M
authors.initials: DM
authors.lastname: Gershenson
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Burke
authors.forename: Rosemarie
authors.initials: R
authors.lastname: Schmandt
authors.forename: Karen H
authors.initials: KH
authors.lastname: Lu
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D015331:Cohort Studies; D016001:Confidence Intervals; D016889:Endometrial Neoplasms / Q000097:blood* / Q000453:epidemiology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D015994:Incidence; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007335:Insulin-Like Growth Factor II / Q000378:metabolism*; D016015:Logistic Models; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D016017:Odds Ratio; D011379:Prognosis; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D014481:United States / Q000453:epidemiology
chemical_list: D014408:Biomarkers, Tumor; D018972:Insulin-Like Growth Factor Binding Protein 3; D007335:Insulin-Like Growth Factor II